ULTRAGENYX PHARMACEUTICAL INC. (RARE) Net margin 2016–2025
ULTRAGENYX PHARMACEUTICAL INC. (RARE) net profit margin by fiscal year — reported net income divided by reported revenue.
-85.4%FY2025 · since FY2016: -184867.7% → -85.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -85.4% | +16.2 pp |
| FY2024 | -101.6% | +38.3 pp |
| FY2023 | -139.9% | +54.8 pp |
| FY2022 | -194.7% | -65.5 pp |
| FY2021 | -129.2% | -60.4 pp |
| FY2020 | -68.8% | +319.5 pp |
| FY2019 | -388.3% | -4.6 pp |
| FY2018 | -383.7% | +11183.6 pp |
| FY2017 | -11567.3% | +173300.3 pp |
| FY2016 | -184867.7% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More RARE financial trends
RARE RevenueRARE Net incomeRARE Gross profitRARE Gross marginRARE Operating incomeRARE Operating marginRARE Operating cash flowRARE Free cash flowRARE Capital expendituresRARE Return on equityRARE Stock buybacksRARE Dividends paidRARE Total assetsRARE Total liabilitiesRARE Shareholders’ equityRARE overview →